PYN Phynova

 

TIDMPYN 
 
RNS Number : 9500S 
Phynova Group PLC 
29 May 2009 
 

29 May 2009 
 
 
Phynova Group plc 
("the Company") 
 
 
Total Voting Rights 
 
 
The Company announces that, pursuant to the requirements of the Disclosure and 
Transparency Rules, the total number of voting rights in respect of each class 
of share in issue and admitted to trading on AIM at the date of this 
announcement is as follows: 
 
 
+-----------------------------------------+--------------+--------------+ 
|                                         |    Number of |   Numbers of | 
|                                         |    shares in |       voting | 
|                                         |        issue |       rights | 
+-----------------------------------------+--------------+--------------+ 
| Ordinary shares of 1p each              |   31,522,520 |   31,522,520 | 
+-----------------------------------------+--------------+--------------+ 
|                                         |              |              | 
+-----------------------------------------+--------------+--------------+ 
 
 
 
 
For further information, please contact: 
 
 
+----------------------------------------------------+---------------------+ 
| Phynova Group PLC                                  |                     | 
+----------------------------------------------------+---------------------+ 
| Steve Harris (Non-Executive Chairman)              | +44 (0) 1993 880700 | 
+----------------------------------------------------+---------------------+ 
| Tony Mills (CEO Phynova Limited)                   |                     | 
+----------------------------------------------------+---------------------+ 
| Robert Miller (CEO Phynova China Limited)          |                     | 
+----------------------------------------------------+---------------------+ 
|                                                    |                     | 
+----------------------------------------------------+---------------------+ 
| Nominated Adviser and Broker:                      |                     | 
+----------------------------------------------------+---------------------+ 
| John East & Partners Limited, a subsidiary of      |     +44 (0) 20 7628 | 
| Merchant Securities PLC                            |                2200 | 
+----------------------------------------------------+---------------------+ 
| John East/Simon Clements                           |                     | 
+----------------------------------------------------+---------------------+ 
|                                                    |                     | 
+----------------------------------------------------+---------------------+ 
 
 
Notes to Editors: 
 
 
About Phynova 
Phynova is a UK company developing new prescription pharmaceuticals derived from 
plants used in Chinese medicines. The Company is focused on viral and bacterial 
diseases, metabolic diseases and cancer. Phynova's lead product for hepatitis C 
has now completed a Phase I/II trial in the US. One further product, for 
post-operative ileus, is targeted for entry to the clinic and there are a 
further four products in preclinical development. 
 
 
For further information please visit www.phynova.com. 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 TVRBBGDUSGDGGCI 
 

Phynova (LSE:PYN)
Historical Stock Chart
From Jan 2025 to Feb 2025

Phynova (LSE:PYN)
Historical Stock Chart
From Feb 2024 to Feb 2025